YX-2-017

N/A

Report date: 2021/12/08 15:31:09
NME

Base Information

Drug NameYX-2-017
Drug Alias NameYX-2-017
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsProteolysis
TargetsCyclin-dependent kinase 6
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSidney Kimmel Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer Center
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A